Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia
Authors Yang Q, Hong JY, Ko YH, Lin S, Au W, Choi MK, Park S, Kim SJ, Kim WS
Received 7 May 2014
Accepted for publication 19 August 2014
Published 26 September 2014 Volume 2014:7 Pages 1717—1722
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 8
Editor who approved publication: Dr Faris Farassati
Qing-Ming Yang,1,* Jung Yong Hong,2,* Young Hyeh Ko,3 Shek-Ying Lin,4 Wing-Yan Au,4 Moon Ki Choi,5 Silvia Park,6 Seok Jin Kim,6 Won Seog Kim6
1The First Affiliated Hospital of the People's Liberation Army General Hospital, Beijing, People's Republic of China; 2Department of Internal Medicine, Chung-Ang University College of Medicine, 3Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; 4Blood-Med Clinic, Hong Kong, People's Republic of China; 5Divisions of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Gyeonggi-do, Korea; 6Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
*Qing-Ming Yang and Jung Yong Hong contributed equally to this work
Introduction: Brentuximab vedotin (SGN-35), an anti-cluster of differentiation (CD)-30 antibody conjugated to the anti-tubulin agent monomethyl auristatin E, has demonstrated promising efficacy and tolerability in relapsed and heavily treated Hodgkin lymphoma (HL). In this study, we report the Asian experience with brentuximab vedotin in patients with relapsed or refractory CD30-positive (CD30+) HL.
Methods: This is an observational, multicenter, retrospective study. Between October 2011 and June 2013, a total of 22 patients were treated with brentuximab vedotin under a named patient program in Asia. Patients received a 30 min infusion of brentuximab vedotin at a dose of 1.8 mg/kg of body weight every 3 weeks.
Results: Four patients (18.2%) showed a complete response, and the overall response rate was 72.7%. The median duration of response was 4.4 months (range 1.0–17.4). The median progression-free survival was 5.7 months, and the median overall survival has not yet been reached. The 1-year expected survival rate was 67.2%. The most common grade 3/4 adverse events were neutropenia (n=7; 31.8%). No patients experienced grade 3/4 sensory neuropathy.
Conclusions: These results confirm that brentuximab vedotin as a single agent is also effective and well tolerated when used in Asian patients with relapsed and refractory CD30+ HL.
Keywords: Asian, efficacy, safety
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]